Result card

  • ORG3: What kind of involvement has to be mobilized for patients/participants and important others?

What kind of involvement has to be mobilized for patients/participants and important others?

Authors: Pseudo117 Pseudo117, Pseudo451 Pseudo451, Pseudo136 Pseudo136, Pseudo262 Pseudo262

Internal reviewers: Pseudo291 Pseudo291, Pseudo340 Pseudo340

Intravenous immunoglobulin (IVIG) is administered by infusion, predominantly in the hospital setting.

Since it is a product with limited availability and high cost, special management programs may be in place regarding its administration to patients such as the Department of Health Demand Management Plan for Immunoglobulin Use in the UK{Department of Health} {4}, the Immunoglobulin (Ig) Governance Program in Australia {National Blood Authority} {5} or the IVIG Utilization Management Program ran by the BC Provincial Blood Coordinating Office (PBCO) in Canada {Provincial Health Services Authority} {6}. Management programs may also be in place at the regional or the hospital level.

According to instructions relating to its administration in other groups of patients for its licensed indications in the aforementioned jurisdictions, patient written consent is required. Information provided to the patients relates to immunoglobulin products; reason for treatment; how the products are given; risks and benefits of the treatment; alternative treatments; side effects; and also requirements regarding collection and sharing of personal private information that apply for  IVIG administration. Patients must also have instructions on how to act if serious reactions after treatment appear.

Pseudo117 P et al. Result Card ORG3 In: Pseudo117 P et al. Organisational aspects In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 19 September 2021]. Available from: